

Index

Pharmacological Reviews

Volume 43

1991

- Acetylcholine, mechanism of action of antipsychotics, 588
 Action potential, extracellular, NRM 5-HT neuron (fig.), 564
 Adenocarcinoma, mammary, nitric oxide synthase, 130
 Adenosine
 agonists and antagonists, cerebellar cGMP (table), 11
 modulators, 6
 receptors for inhibitory agonists, 275
 uptake and metabolism, 279
 Adenosine 5'-diphosphate
 extracellular, metabolism, 255
 receptors for stimulatory agonists, 250
 Adenylate cyclase
 activation, ventricular G proteins, myopathy (table), 218
 activation in end-stage ICM, ventricular G proteins (table), 221
 α_2 -adrenoceptor-mediated inhibition (fig.), 492
 coupling, *beta* adrenoceptors, 207
 Adenylyl cyclase, inhibition, 486
 Adrenal gland, cyclic GMP levels, 124
 Adrenaline
 -induced positive inotropic effects, left papillary muscles (fig.), 211
 -induced stimulation of left ventricular adenylate cyclase, antagonism, *beta* adrenoceptors (fig.), 208
 Adrenoceptors
 agonists and antagonists (table), 477
 alpha
 guanine nucleotide regulatory proteins, 490
 molecular biology, 500
 occupancy and function, 488
 proposed interaction (fig.), 493
 signal transduction, 500
 signal transduction mechanisms, 483
 structure and function, 475
 subclassification, 499
 alpha-1
 cloning of DNAs, 493
 competition by agonists and antagonists (table), 495
 functional expression, cDNAs, 495
 heterogeneity, 477
 alpha-2
 alignment of amino acid sequences (fig.), 496
 cloning of DNAs, 496
 DNA expression, 498
 heterogeneity, 480
 occupancy, signal transduction mechanisms, 489
 primary structure, kidney (fig.), 497
 signal transduction processes, mathematical model (fig.), 491
 sodium-hydrogen exchange (fig.), 488
 alpha-1 and *alpha*-2 classification, 476
 beta
 agonists, maximal positive inotropic effects (fig.), 220
 agonists, spare receptors in heart, 224
 alterations, chronic heart failure, 223
 antagonism, stimulation of left ventricular adenylate cyclase (fig.), 208
 antagonist radioligands (table), 205
 antagonists, 228
 antagonists, right atria (fig.), 229
 density, left ventricle (fig.), 225
 effects of drugs, human heart, 228
 failing human heart, 216
 heart failure (fig.), 217
 human heart, 203
 left ventricular membranes (fig.), 205
 maximal positive inotropic effect, right ventricular trabeculae (fig.), 227
 6 months treatment, metoprolol (fig.), 230
 myocardial, subtype distribution (table), 222
 nonfailing human heart, 205
 positive inotropic drugs, 213
 procaterol and noradrenaline (fig.), 229
 protein phosphorylation, 321
 subtype distribution, heart failure (table), 218
 subtype distribution, nonfailing human heart (table), 206
 transplanted human heart, 226
 Afferents, noradrenergic, 13
 Ahlner, Johan, Rolf G. G. Andersson, Kristina Torfgård, and Krister L. Axelsson. Organic nitrate esters: Clinical use and mechanisms of actions, 351
 Airway diseases, nitrates, 391
 Alcoholism, synapsin variants, 329
 Alprazolam, stress and, corticotropin-releasing factor concentrations (fig.), 455
 Alzheimer's disease
 alterations, regional brain corticotropin-releasing factor concentrations and receptors, 460
 CRF-like immunoreactivity, receptor binding (fig.), 460
 protein phosphorylation, 331
 serotonin, 519
 studies of *m*-chlorophenylpiperazine, 532
 Amantadine, changes in motor activity, cerebellar cGMP (table), 3
 Amino acids
 alignment of sequences, *alpha*-2 adrenoceptors (fig.), 496
 branched-chain, 56
 branched-chain and aromatic, "false" neurotransmitters, 37
 excitatory
 GABAergic pathways and, 4
 nonselective antagonists, 14
 release, 13
 γ -Aminobutyric acid
 -benzodiazepine receptor complex, 42
 -BzR/chloride ionophore supramolecular complex (fig.), 42
 excitatory amino acids and, 4
 mechanism of action of antipsychotics, 588
 receptor complex organization, 41
 γ -Aminobutyric acid-A, benzodiazepine receptor modulators, 5
 γ -Aminobutyric acid-B, receptor agonists, 6
 Ammonia, major contributor, hepatic encephalopathy, 35
 Amperozide
 pED₅₀ (table), 594
 pK_i values (table), 592

- D-Amphetamine, changes in motor activity, cerebellar cGMP (table), 3
- β -Amyloid, precursor protein phosphorylation, neuritic plaques, 333
- Analgesia, brain 5-HT, 567
- Andersson, Rolf G. G. *See* Ahlner et al., 351
- Anesthetics, barbiturates and, cGMP in the cerebellum, 12
- Angina
- stable, organic nitrates, 382
 - unstable, silent myocardial ischemia, myocardial infarction, 387
 - vasospastic
 - glyceryl trinitrate, 386
 - isosorbide dinitrate and isosorbide-5-mononitrate, 386
- Angiotensin-converting enzyme inhibitors, *beta* adrenoceptors, 231
- Anorexia nervosa, endocrine and cerebrospinal fluid studies, 460
- Antibiotics, hepatic encephalopathy, 55
- Anticonvulsants, cerebellar cGMP (table), 10
- Antidiuretic hormone, disorders (table), 98
- Antiemesis, 5-HT₃ receptor agents, 582
- Antipsychotics
- atypical, 588
 - pED₅₀ (table), 594
 - pK_i values, 5-HT₂ (table), 592
 - serotonin receptor antagonism, 598
 - binding properties, serotonin receptors, 592
 - clinical studies, 599
 - cortical 5-HT₂ and striatal pK_i values (table), 593
 - effects on serotonin receptors, 587
 - mechanism of action, neurotransmitters, 588
 - pK_d or pK_i values, 5-HT receptors (table), 592
 - serotonin class 3 receptor antagonism, 598
 - serotonin-mediated behavior, 597
- Anxiety
- animal models, 449, 544
 - depression and, animal models, 537
- Anxiety disorder
- serotonin function, 516
 - studies of azapirones, 542
- Aorta
- effect of dexamethasone, constitutive and inducible nitric oxide synthase (fig.), 132
 - time-dependent loss of tone, effect of cycloheximide, L-NIO (fig.), 130
- Apomorphine, changes in motor activity, cerebellar cGMP (table), 3
- Arachidonic acid, metabolites, vascular actions, organic nitrate esters, 366
- L-Arginine
- citrulline synthesis, Ca²⁺ dependence, nitric oxide (fig.), 123
 - platelet aggregation, nitric oxide synthesis (fig.), 121
 - structural formulae (fig.), 116
- Arginine vasopressin
- elevated plasma levels, V₁ antagonists, 96
 - ethanol-induced gastric lesions (fig.), 87
- Arylpiperazines, serotonin-selective, effects in humans, 527
- Aspirin, indomethacin and, drug interactions, nitrates, 406
- Atenolol
- human cardiac *beta* adrenoceptors (fig.), 213
 - propranolol and, tachycardia (fig.), 212
- Atropine, human cardiac *beta* adrenoceptors (fig.), 213
- Aulakh, C. S. *See* Murphy et al., 527
- Axelsson, Krister L. *See* Ahlner et al., 351
- Azapirones
- food intake, 544
 - healthy normal subjects, 541
 - 5-HT_{1A} receptors, 541
 - in vitro* and in animals, 543
 - locomotor activity, 544
 - neurochemical effects, 543
 - neuroendocrine measures, 544
 - patients with neuropsychiatric disorders, 542
- Barbiturates, anesthetics and, cGMP in the cerebellum, 12
- Basile, Anthony S., E. Anthony Jones, and Phil Skolnick. The pathogenesis and treatment of hepatic encephalopathy: Evidence for the involvement of benzodiazepine receptor ligands, 27
- Behavior
- anxiety and depression, animal models, 449
 - corticotropin-releasing factor regulation, laboratory animals, 448
 - feeding, corticotropin-releasing factor, 449
 - locomotor activation, corticotropin-releasing factor, 448
 - oral-buccal movements, 573
 - serotonin-mediated, antipsychotic drugs, 597
 - serotonin-selective arylpiperazines, 527
 - sexual, corticotropin-releasing factor, 448
- Benzodiazepine
- ligands (fig.), 43
 - nuclei biosynthesis (fig.), 52
- Bioassay, vasopressin antagonists, 75
- Blood pressure
- changes induced by oral administration, L-NAME and L-NMMA (fig.), 117
 - DRN 5-HT neuron (fig.), 574
 - regulation, V₁ antagonists, 78
- Blood vessels, relaxant effect of glyceryl trinitrate (table), 355
- BMJ 25801, BRL 24924 and, clinical status (table), 583
- Brain
- cerebral aqueduct or locus ceruleus, corticotropin-releasing factor infusion (fig.), 450
 - developmental pharmacology, serotonin, other neurotransmitter, 553
 - energy metabolism, *m*-chlorophenylpiperazine, 538
 - first messengers regulating second messenger generation (table), 303
 - hypothalamic corticotropin-releasing factor neurons, actions of cytokines, 444
 - insulin-induced hypoglycemia, corticotropin-releasing factor mRNA (fig.), 441
 - localization, corticotropin-releasing factor receptors, 433
 - major corticotropin-releasing factor-stained cell groups, fiber systems (fig.), 429
 - nigrostriatal and mesolimbic pathway, serotonergic innervation, 590
 - nigrostriatal pathways, serotonergic regulation, dopaminergic function, 595
 - pED₅₀, typical atypical antipsychotic drugs (table), 594
 - phosphoprotein phosphatases, 312
 - prevention of hyponatremia and cerebral edema, V₂ antagonists, 88
 - serine/threonine-specific protein phosphatases (table), 312
 - serotonergic neurons, behaving animal, 563
 - specific regions, topical administration, capsaicin, 164
 - water content, serum osmolality, vasopressin antagonist (table), 90
- Brodde, Otto-Erich. β_1 - and β_2 -adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure, 203
- Bulimia, migraine and, 532
- Buspirone
- neuroendocrine responses, 514
 - single-dose studies in humans, 541
- Calcium
- antagonists, 230
 - dependence of nitric oxide and citrulline synthesis, L-arginine, brain synaptosomal cytosol (fig.), 123
 - dependent protein kinases, 306, 308
 - homeostasis, organic nitrate esters, cyclic GMP, 363
 - independent nitric oxide synthase (fig.), 129
 - influx, phosphorylation of GAP-43, 318
 - peak positive left ventricular dP/dT (fig.), 223
 - phospholipid-dependent protein kinases, 309

- signal transduction, second messenger systems, 433
- sodium chloride and, intracellular accumulation, neurotoxicity, 181
- translocation, *alpha* adrenoceptor signal transduction, 483
- Calcium channels, voltage-dependent, 324
- Calcium current, capsaicin administration, 176
- Capsaicin
 - action
 - excitable cells (table), 188
 - neurons, 189
 - primary afferent neurons, 145
 - acute and long-term effects, nonmammalian species, 168
 - acute excitatory effects, mammalian sensory neurons, 146
 - administered to central endings, afferent neurons, 163
 - administered to peripheral endings, sensory neurons, 164
 - biochemical characterization, recognition site, 174
 - cell-nonspecific effects, 169
 - cellular targets, mechanisms of action, selectivity for thin sensory neurons, 143
 - differences in sensitivity, mammalian species, 166
 - interaction with nerve growth factor, 184
 - intermediate effects, mammalian sensory neurons, 150
 - intracerebroventricular application, 163
 - like substances, 186
 - long-term neurotoxic effects, mammalian sensory neurons, 151
 - mechanisms of action, 170
 - mechanisms of cell-nonspecific effects, 187
 - ontogenetic shift in neurotoxicity, rat, 186
 - periaxonal administration, 160
 - pharmacological tool, 189
 - pharmacological tool (table), 190
 - primary afferent neurons, markers (table), 146
 - resiniferatoxin and, chemical structure (fig.), 145
 - routes of administration, 190
 - ruthenium red as functional antagonist, 182
 - selectivity of action, 155, 158, 160
 - sensitivity, age and strain differences, mammalian species, 167
 - sensory neurons in culture, 165
 - sensory neurons *in vitro*, 165
 - systemic
 - adult mammals, 156, 160
 - newborn mammals, 151
 - targets and selectivity
 - excitable cells, mammals (table), 148
 - excitatory action, 147
 - topical administration, specific brain regions, 164
- Capsaicinoids
 - desensitizing and neurotoxic effects, structure-activity relationships, 171
 - excitatory effect, structure-activity relationship, 170
- Capsozepine, competitive antagonist of capsaicin, 173
- Cardiovascular system
 - corticotropin-releasing factor regulation, autonomic function, other peripheral actions, 446
 - inhibition of nitric oxide synthesis, 114
 - regulation, 5-HT neurons, 573
 - serotonin-selective arylpiperazines, 527
- Casein kinase, DARPP-32 cells, 311
- Catalepsy, neuroleptic-induced, effect of serotonin, 595
- Catecholamines
 - binding studies, 256
 - false neurotransmitter hypothesis, 39
 - α -receptor, 255
 - β -receptor, 284
 - structure-activity relationships, 256
 - uptake and metabolism, 257
- Central nervous system
 - localization of corticotropin-releasing factor, 428
 - neuroanatomical relationship, serotonergic and dopaminergic systems, 589
- nitric oxide, 122
- Cerebellum
 - basic circuitry diagram (fig.), 4
 - cell fractions, 4
 - cyclic GMP and, motor activity, dopaminergics (table), 3
 - drug effects on cerebellar cGMP (table), 7
 - pharmacology of cyclic guanosine 3',5'-monophosphate, 1 slices, 4
- Cerebrospinal fluid
 - corticotropin-releasing factor concentrations, 458
 - schizophrenia (fig.), 459
 - endocrine studies and, anorexia nervosa, 460
 - 5-hydroxyindoleacetic acid, 511
- Chloride channel, regulation, cystic fibrosis, 329
- 6-Chloro-2-(1-piperazinyl)pyrazine, studies in humans, 539
- m-Chlorophenylpiperazine
 - food intake, 534
 - locomotor activity, 536
 - neuroendocrine measures, 535
 - other substituted phenylpiperazines and, 529
 - patients with neuropsychiatric disorders, 530
 - related piperazines and, *in vitro* and in animals, 532
 - temperature, 534
- Chlorpromazine, pED₅₀ (table), 594
- Cholecystokinin peptides, cerebellar cGMP (table), 9
- Choline
 - modulators, 18
 - serotonergic interactions, 520
- Cholinergics, cerebellar cGMP (table), 8
- Circadian rhythm
 - corticotropin-releasing factor regulation, neuroendocrine function, 435
 - sleep-wake-arousal cycle, 564
- Cirrhosis, amelioration of hepatic encephalopathy (fig.), 59
- Citrulline, synthesis from L-arginine, Ca²⁺ dependence, nitric oxide (fig.), 123
- Climbing fiber system, cGMP in the cerebellum, 15
- Clozapine
 - atypical antipsychotic drugs, 588
 - pED₅₀ (table), 594
 - pK_i values (table), 592
- Coccaro, Emil F. *See* Siever et al., 509
- Collagen, blood platelet receptors, 271
- Convulsants, cerebellar cGMP (table), 10
- Coronary vessels, nitrate esters, 380
- Corticotropin-releasing factor
 - administration
 - gastrointestinal responses, 447
 - metabolic responses, 447
 - analgesic and anti-inflammatory properties, 445
 - autonomic actions (fig.), 446
 - binding in rat olfactory bulb membranes, 433
 - cerebrospinal fluid concentrations, 458
 - concentrations, alprazolam and stress (fig.), 455
 - concentrations and receptors, Alzheimer's disease, 460
 - containing neurons and receptors, 428
 - electrophysiological responses, 451
 - historical perspectives, 426
 - hypersecretion, pathophysiology, psychiatric illness, 457
 - hypophysiotropic system, ontogeny of, 435
 - infusion, animals in darkened compartment (fig.), 450
 - like immunoreactivity, receptor binding, Alzheimer's disease (fig.), 460
 - local gonadal actions, 448
 - localization in peripheral tissues, 430
 - localization of messenger RNA, 432
 - messenger RNA, insulin-induced hypoglycemia (fig.), 441

- neurons
 - actions of cytokines, 444
 - effects of stress, 453
 - extrahypothalamic, miscellaneous changes, 456
 - extrahypothalamic, pharmacological manipulation, 454
 - feedback and stress-induced effects, 439
 - nonhypophysiotropic, pharmacological and environmental perturbation, 453
 - other endocrine functions, 441
 - responses, miscellaneous manipulations, 442
- peptide and messenger RNA localization, 428
- physiology and pharmacology, 425
- pituitary corticotrophs, 436
- potentiation of action on corticotroph, 437
- pressure application, different neurons (fig.), 451
- receptors, 433
 - anterior pituitary, feedback- and stress-induced effects, 441
- regulation
 - autonomic function, other peripheral actions, 446
 - behavior, laboratory animals, 448
 - immune function, 444
 - neuroendocrine function, 435
 - neuron, neurotransmitter regulation, 437
- reproductive hormone function, 442
- stained cell groups and fiber systems, rat brain (fig.), 429
- stimulation test, 457
- Corticotropin-releasing hormone, gene, structural organization, rat (fig.), 433
- Cusack, Noel J. *See* Hourani and Cusack, 243
- Cyclic AMP, contractile force, time course of effects, isoprenaline (fig.), 209
- Cyclic GMP
 - action of organic nitrate esters, 357
 - cerebellar
 - antagonism by drugs (table), 15
 - drug and behavioral effects, stress, 3
 - drug effects (table), 7
 - modulation, NO synthetase inhibitor (table), 14
 - changes in motor activity, dopaminergics (table), 3
 - confounding variables, 2
 - dependent protein kinase, 306
 - diagram of basic components (fig.), 357
 - lesions and mutant mice, 2
 - logit-log dose-response curves, CPP and tiletamine (table), 14
 - microwave tissue fixation, 2
 - mouse cerebellar, antagonists, EAA-dependent increases (table), 15
 - organic nitrate esters, cellular calcium homeostasis, 363
 - pharmacology of, cerebellum, 1
 - relation to mode of action, organic nitrate esters, 359
 - routes of drug administration, 2
 - schematic drawing showing cellular mechanisms, mediation, vascular smooth muscle relaxation (fig.), 365
 - tissue microdissection, 2
- Cycloheximide
 - dexamethasone and, induction, nitric oxide synthase (fig.), 132
 - L-NIO and, time-dependent loss of tone, aorta (fig.), 130
- Cystic fibrosis, chloride channel regulation, 329
- Cytokines, actions on hypothalamic corticotropin-releasing factor neurons, 444
- Denopamine, *beta* adrenoceptors, 214
- Depressants, cerebellar cGMP (table), 10
- Depression
 - animal models, 449, 544
 - anxiety and, animal models, 537
 - major
 - corticotropin-releasing factor hypersecretion, 457
 - signs and symptoms (table), 451
 - studies of azapirones, 542
 - studies of *m*-chlorophenylpiperazine, 531
- N*-Desmethyldiazepam
 - diazepam and (fig.), 51
 - summary of levels (fig.), 53
- De Wied, David. *See* L     et al., 73
- Dexamethasone
 - constitutive and inducible nitric oxide synthases, rat aorta (fig.), 132
 - cycloheximide and, induction, nitric oxide synthase (fig.), 132
- Diazepam
 - N*-desmethyldiazepam and (fig.), 51
 - summary of levels (fig.), 53
- Diet, hepatic encephalopathy, 55
- Dihydroergotamine, sumatriptan interactions, neurotransmitter receptor (table), 581
- DNA
 - α_2 -adrenoceptor, 498
 - cloning of α_1 -adrenoceptor, 493
- DNA, complementary
 - α_1 -adrenoceptor, functional expression, 495
 - alpha*-2 adrenoceptor cloning, 496
- Dobutamine
 - beta* adrenoceptors, 214
 - left ventricular dP/dT, dilated cardiomyopathy (fig.), 230
 - peak positive left ventricular dP/dT (fig.), 223
- Dopamine
 - beta* adrenoceptors, 214
 - mechanism of action of antipsychotics, 588
 - mediated behavior, mesolimbic pathway, effect of serotonin, 597
 - mesolimbic pathways, effect of serotonin, 597
 - modulators, 16
 - regulation of natriuresis, 330
 - serotonergic regulation, 595
 - serotonin and, 520
 - neuroanatomical relationship, 589
- Dopaminergics, changes in motor activity, cerebellar cGMP (table), 3
- Dopexamine, *beta* adrenoceptors, 214
- Drug discrimination
 - animal models, anxiety and depression, 544
 - anxiety and depression, animal models, 537
- EAA, -dependent increases, antagonists, mouse cerebellar cGMP levels (table), 15
- EAA agonists, antagonists and, cerebellar cGMP (table), 11
- Edema, cerebral, prevention of hyponatremia, V_2 antagonists, 88
- Electroencephalography, convulsive studies and, 452
- Electrophysiology
 - m*-chlorophenylpiperazine, 533
 - mesolimbic dopamine pathways, effect of serotonin, 597
 - responses to corticotropin-releasing factor, 451
 - serotonergic regulation, dopaminergic function, 595
- Emesis, 5-HT₃ receptor agents, 582
- Encephalopathy
 - hepatic
 - amelioration (fig.), 59
 - animal models, 34
 - behavioral characteristics of rabbit (table), 34
 - benzodiazepine ligands, rat brains (fig.), 50
 - benzodiazepine ligands (fig.), 49
 - benzodiazepine receptor ligands (fig.), 46
 - benzodiazepine receptor ligands, 48
 - chronic, 54
 - clinical manifestations, 29
 - clinical stages (table), 30
 - complications of liver disease, 54
 - definition, 28
 - development of, traditional concepts (fig.), 33

- electrophysiology, 31
- GABA/benzodiazepine receptor complex, 42
- improvement of hepatocellular function, 54
- insufficiency and vascular rearrangement (fig.), 29
- metabolites found in abnormal levels (table), 34
- neuropathology, 30
- pathogenesis and treatment, 27
- precipitating factors, 53
- proposed mechanisms of pathogenesis, 32
- reduction, portal-systemic shunting, 54
- therapeutic modalities, 53, 54
- Endothelial cells, Ca^{2+} -independent nitric oxide synthase, time course of induction (fig.), 129
- Endothelium, interaction with organic nitrate esters, 370
- Endothelium-derived relaxing factor
 - controversy about chemical identity, 112
 - identification as nitric oxide, 111
 - nitric oxide and, comparison of stability (fig.), 112
- Enzyme, activation, capsaicin, 177
- Epinephrine, β adrenoceptors, 214
- Ethanol
 - cGMP in the cerebellum, 12
 - corticotropin-releasing factor, actions on HPA axis, 443
 - induced gastric lesions, plasma AVP (fig.), 87
- Ethylene glycol dinitrate, concentration-effect curve (fig.), 355
- Exercise, pharmacokinetics of glyceryl trinitrate, 373
- Fatty acids, central nervous system electrical activity, 39
- Fenfluramine
 - neuroendocrine responses, 512
 - responses, extrahypothalamic corticotropin-releasing factor neurons, 454
- Fibroblasts, generation of nitric oxide, 130
- Flumazenil
 - antagonist to benzodiazepine, 57
 - efficacy in clinical trials (table), 59
 - pharmacological properties, 58
 - potential clinical use, 58
 - remission of chronic intractable PSE (fig.), 60
- Fluprelapine
 - pED_{50} (table), 594
 - pK_i values (table), 592
- Fluphenazine, pED_{50} (table), 594
- Fornal, Casimir A. *See* Jacobs and Fornal, 562
- Forskolin, heart rate response to increasing doses, bolus injections (fig.), 224
- GABAergic agents, cerebellar cGMP (table), 9
- GAP-43, phosphorylation by Ca^{2+} influx, 318
- Gastric circulation
 - mucosa, V_1 antagonist (fig.), 86
 - role of vasopressin, cytoprotection (fig.), 86
 - vasopressin antagonists, 84
- Gastrointestinal system, corticotropin-releasing factor administration, 447
- Gene, corticotropin-releasing hormone, structural organization, rat (fig.), 433
- Genetic disorders, role of corticotropin-releasing hormone, animal models, 443
- Glucocorticoids, immunologically induced formation, nitric oxide, 131
- Glucose
 - DRN 5-HT neuron and cortical EEG (fig.), 572
 - implication of brain 5-HT, 571
- Glyceryl trinitrate
 - absorption and bioavailability, 374
 - analysis of, 371
 - analytic methods for GC determination (table), 372
 - buccal and oral, tolerance development, 393
 - concentration-effect curve (fig.), 355
 - congestive heart failure, 389
 - distribution, 374
 - handling of samples, 372
 - influence of posture, 373
 - influence of sampling site, 372
 - intravenous, tolerance development, 392
 - invention of, 353
 - isoprenaline and, induced hypotension, effect of L-NIO (fig.), 119
 - lactate production, ventricular heart muscle (fig.), 363
 - metabolism and elimination, 375
 - ointment and patches, 393
 - oxygen consumption, ventricular heart muscle (fig.), 366
 - pharmacokinetic data, 374
 - pharmacokinetics, effect of exercise, 373
 - pharmacokinetic studies, 370
 - relaxant effect on blood vessels (table), 355
 - route of administration, 373
 - sorption to materials, 370
 - stable angina pectoris, 382
 - tolerance development, 392
- Glycine, NMDA-associated agonists, 13
- Glycogen synthase kinase 3, regulation of cell-cell interactions, 311
- Gonads, local actions, corticotropin-releasing factor, 448
- G-proteins
 - α -adrenoceptor function, 490
 - coupled receptor proteins, schematic model (fig.), 494
 - coupled receptors, 321
 - ventricular
 - adenylate cyclase activation, myopathy (table), 218
 - adenylate cyclase activation, end-stage ICM (table), 221
- Granisetron
 - antiemesis, 582
 - clinical status (table), 583
- Greengard, Paul. *See* Walaas and Greengard, 299
- Growth hormone, secretion, corticotropin-releasing factor neurons, 441
- Guanylate cyclase
 - characteristics of Nervous and Weaver mice (table), 3
 - proposed scheme for NMDA augmentation (fig.), 21
 - soluble, transduction mechanism, nitric oxide, 110
- Guinea pig, long-term neurotoxic effects, capsaicin, mammalian sensory neurons, 159
- Haloperidol, pED_{50} (table), 594
- Heart
 - aortic valve disease, 223
 - atrial tissues, positive inotropic effects, 209
 - autonomic actions, corticotropin-releasing factor (fig.), 446
 - biventricular failure, ventricular β adrenoceptors, subtype distribution (table), 218
 - chronic failure, alterations, β adrenoceptors, 223
 - circulation, vasopressin antagonists, 81
 - congestive failure, nitrates, 389
 - dilated cardiomyopathy, dobutamine, left ventricular dP/dT (fig.), 230
 - end-stage dilated cardiomyopathy, ventricular G proteins (table), 218
 - end-stage ischemic cardiomyopathy, 220
 - ventricular G proteins (table), 221
 - failing, β adrenoceptors, 216
 - failure, β adrenoceptors (fig.), 217
 - human
 - β adrenoceptors, 203
 - effects of drugs, β adrenoceptors, 228
 - hypertrophic obstructive cardiomyopathy, 223
 - idiopathic dilated cardiomyopathy, 217
 - left ventricle, density, β adrenoceptors (fig.), 225
 - left ventricular membranes
 - antagonism of stimulation, β adrenoceptors (fig.), 208

- determination, *beta* adrenoceptors (fig.), 205
- mitral valve disease, 221
- myocardial *beta* adrenoceptors, subtype distribution (table), 222
- nonfailing
 - beta* adrenoceptors, 205
 - numbers of *beta* adrenoceptors, subtype distribution (table), 206
- nonfailing or end-stage DCM, maximal positive inotropic effects, *beta* adrenoceptors (fig.), 220
- peak positive left ventricular dP/dT, dobutamine or calcium gluconate infusion (fig.), 223
- right atria
 - beta* adrenoceptor antagonists (fig.), 229
 - isoprenaline-induced positive inotropic effect (fig.), 210
 - procaterol and noradrenaline (fig.), 229
- spare receptors, *beta* adrenoceptor agonists, 224
- tetralogy of Fallot, 223
- transplanted human, *beta* adrenoceptors, 226
- V₁ antagonist, perfusion pressure changes (fig.), 82
- vasoconstriction, vasopressin analogues (fig.), 82
- ventricular muscle, lactate production, glyceryl trinitrate (fig.), 363
- ventricular tissues, 210
- Heart rate
 - DRN 5-HT neuron (fig.), 574
 - firing rate of DRN 5-HT neurons (fig.), 570
 - isoprenaline-induced increases (fig.), 212
 - response to bolus injections, isoprenaline and forskolin (fig.), 224
- Hemodynamics, peripheral, nitrate esters, 378
- Heparin, drug interactions, nitrates, 406
- Hepatocytes, Kupffer cells and, nitric oxide, 129
- Hieble, J. Paul. *See* Ruffolo et al., 475
- Higgs, E. A. *See* Moncada et al., 109
- Histamine
 - mechanism of action of antipsychotics, 588
 - nitric oxide, 124
- Holzer, Peter. Capsaicin: Cellular targets, mechanisms of action, and selectivity for thin sensory neurons, 143
- Hourani, Susanna M. O. and Noel J. Cusack. Pharmacological receptors on blood platelets, 243
- HP-370, pED₅₀ (table), 594
- 5-Hydroxyindoleacetic acid
 - cerebrospinal fluid, 511
 - patients with affective and personality disorders, 515
 - receptor subtypes, 515
- 5-Hydroxytryptamine
 - binding studies and receptor isolation, 259
 - structure-activity relationships, 258
 - uptake and metabolism, 259
- Hypertension, DRN 5-HT neuron (fig.), 575
- Hypoglycemia, insulin-induced, corticotropin-releasing factor mRNA (fig.), 441
- Hyponatremia, cerebral edema and, prevention of, V₂ antagonists, 88
- Hypotension, induced by isoprenaline and GTN, effect of L-NIO (fig.), 119
- ICI 204,636, cortical 5-HT₂ and striatal pK_i values (table), 593
- ICS 205-930, antiemesis, 582
- N-Iminoethyl-L-ornithine
 - cycloheximide and, time-dependent loss of tone, aorta (fig.), 130
 - hypotension induced by isoprenaline and GTN (fig.), 119
 - platelet anti-aggregatory activity (fig.), 126
- Imipramine, binding with platelets, 512
- Immune function, regulation, corticotropin-releasing factor, 444
- Indole, modulators, 19
- Insulin
 - DRN 5-HT neuron and cortical EEG (fig.), 572
 - induced hypoglycemia, corticotropin-releasing factor mRNA (fig.), 441
- Interferon- γ , Ca²⁺-independent nitric oxide synthase, time course of induction (fig.), 129
- Ion channels
 - regulation, 322
 - regulation following intracellular injection, protein kinases, nerve cells (table), 323
- Ionophores, GABA/BzR/chloride, supramolecular complex (fig.), 42
- Ipsapirone, single-dose studies in humans, 541
- Isoprenaline
 - contractile force and cAMP (fig.), 209
 - GTN and, induced hypotension, effect of L-NIO (fig.), 119
 - heart rate response to increasing doses, bolus injections (fig.), 224
 - induced increases in heart rate (fig.), 212
 - induced positive inotropic effect, right atria (fig.), 210
 - induced stimulation of left ventricular adenylate cyclase, antagonism, *beta* adrenoceptors (fig.), 208
 - percentage of receptor occupancy, positive inotropic effect (fig.), 226
- Isosorbide dinitrate
 - absorption and bioavailability, 376
 - distribution, 377
 - isosorbide-5-mononitrate and congestive heart failure, 389
 - pharmacokinetic data, 376
 - stable angina pectoris, 384
 - metabolism and elimination, 377
 - tolerance development, 394
- isosorbide-5-mononitrate, tolerance development, 394
- Jacobs, Barry L. and Casimir A. Fornal. Activity of brain serotonergic neurons in the behaving animal, 562
- Jones, E. Anthony. *See* Basile et al., 27
- Kahn, René S. *See* Siever et al., 509
- Kainate, low-dose response curves, mouse cerebellar cGMP (fig.), 13
- Kidney
 - α -2 adrenoceptor, primary structure (fig.), 497
 - autonomic actions, corticotropin-releasing factor (fig.), 446
 - hemodynamic changes, V₁ antagonist (fig.), 84
- Kupffer cells, hepatocytes and, nitric oxide, 129
- Lactulose, related carbohydrates and, hepatic encephalopathy, 56
- László, Ferenc, Jr. *See* László et al., 73
- László, Ferenc A., Ferenc László, Jr., and David De Wied. Pharmacology and clinical perspectives of vasopressin antagonists, 73
- Lawlor, Brian A. *See* Siever et al., 509
- Lawrence, Timothy L. *See* Siever et al., 509
- Lergotrile, changes in motor activity, cerebellar cGMP (table), 3
- Lesch, K. P. *See* Murphy et al., 527
- Ligands
 - benzodiazepine
 - hepatic encephalopathy, rabbits (fig.), 49
 - hepatic encephalopathy, rat brains (fig.), 50
 - summary of levels (fig.), 53
 - benzodiazepine receptor
 - hepatic encephalopathy, 27
 - open field performance, hepatic encephalopathy (fig.), 46
 - sigma, 14
- Lipopolysaccharide, Ca²⁺-independent nitric oxide synthase, time course of induction (fig.), 129
- Liver, nitric oxide synthase activity, lipopolysaccharide (fig.), 131
- Locomotion
 - azapirones, 544
 - m*-chlorophenylpiperazine, 535
- Long-term potentiation, regulation of, 327
- Loxapine, pED₅₀ (table), 594
- Macrophages
 - effect of L-NMMA (fig.), 128
 - synthesis of nitric oxide, 124

Mammals

- adult, systemic capsaicin, 156
- differences in sensitivity
 - age and strain differences, 167
 - capsaicin, 166
- newborn, systemic capsaicin, 151, 155, 157

MAP-2, phosphorylation, 332

MARCKS protein, phosphorylation, 317

Mass spectrometry, ¹⁵NO release from porcine aortic endothelial cells (fig.), 114

MDL 72222, clinical status (table), 583

Melperone

- pED₅₀ (table), 594
- pK_i values (table), 592

Meltzer, Herbert Y. and J. Frank Nash. Effects of antipsychotic drugs on serotonin receptors, 586

Mental illness, neuropeptide therapy, 461

1-(2-Methoxyphenyl)piperazine, studies in humans, 540

N-Methyl-D-aspartate

- associated glycine agonists, 13
- associated glycine receptor antagonists, 14
- augmentation, proposed scheme (fig.), 21
- low-dose response curves, mouse cerebellar cGMP (fig.), 13

Methylphenidate, changes in motor activity, cerebellar cGMP (table), 3

Metoprolol, 6 months treatment, *beta* adrenoceptor density, heart (fig.), 230

Mice

- characteristics of Nervous and Weaver strains (table), 3
- mutant, cyclic GMP, 1

Microtubule proteins, phosphorylation, 331

Migraine

- bulimia and, 532
- sumatriptan, 579

Moncada, S., R. M. J. Palmer, and E. A. Higgs Nitric oxide: Physiology, pathophysiology, and pharmacology, 109

Monoaminergic agents, cerebellar cGMP (table), 7

N-Monomethyl-L-arginine, modulation of cerebellar cGMP, NO synthetase inhibitor (table), 14

N^G-Monomethyl-L-arginine

- changes in blood pressure (fig.), 117
- effect on aortic pressure (fig.), 116
- leishmanicidal activity, activated macrophages (fig.), 128
- platelet anti-aggregatory activity (fig.), 126

Morphine

- response of single NRM 5-HT neuron (fig.), 569
- tail-flick test, NRM 5-HT neurons (fig.), 567

Mossy fiber system

- anatomy/neurochemistry, 16
- pharmacology, 16
- polysynaptic circuitry (fig.), 17

Murphy, D. L., K. P. Lesch, C. S. Aulakh, and T. A. Pigott. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans, 527

Muscimol, Purkinje neuron responses (fig.), 44

Muscle, smooth

- sumatriptan effects, 580

vascular

- cellular mechanisms, cyclic GMP (fig.), 365
- cyclic GMP system, organic nitrate esters, 359
- hyperpolarization, 366
- relaxant action, organic nitrate esters (fig.), 370

Myelin basic protein kinase, phosphorylation, 311

Myocardial infarction

- glyceryl trinitrate, 388
- unstable angina, 387

Myocardial ischemia, unstable angina, 387

Myocardium, cyclic GMP system, organic nitrate esters, 359

Nash, J. Frank. *See* Meltzer and Nash, 586

Natriuresis, dopaminergic regulation, 330

Nemeroff, Charles B. *See* Owens and Nemeroff, 425

Nerve

- alveolar, stimulation, NRM 5-HT neurons (fig.), 569
- conduction, blockade of, 151
- neurogenic inflammation, 581

Nerve cells

- functional importance, second messenger-regulated protein kinases, 305
- regulation of ion channels, intracellular injection, protein kinases (table), 323

Nerve growth factor, interaction with capsaicin, 184

Nerve terminal

- phosphoproteins, presynaptic receptors, 319
- protein phosphorylation, depolarization-induced Ca²⁺ influx (table), 316

Nervous system, function, protein kinases (table), 304

Neuritic plaques, β -amyloid precursor protein phosphorylation, 333

Neurochemistry, *m*-chlorophenylpiperazine, 533

Neuroendocrine function, corticotropin-releasing factor regulation, 435

Neuroendocrinology, *m*-chlorophenylpiperazine, 535

Neurofibrillary tangles, tau factor phosphorylation, 332

Neurofilament proteins, phosphorylation, 331

Neurons

- afferent, central endings, capsaicin administration, 163
- capsaicin-sensitive, 169
- corticotropin-releasing factor
 - actions of cytokines, 444
 - distribution, 428
 - effect of pressure application (fig.), 451
 - effects of stress, 453
 - extrahypothalamic, pharmacological manipulation, 454
 - feedback and stress-induced effects, 439
 - nonhypophysiotropic, pharmacological and environmental perturbation, 453
 - other endocrine functions, 441
 - regulation, 437
 - responses, miscellaneous manipulations, 442

DRN 5-HT

- cortical EEG (fig.), 572
- firing rate, heart rate (fig.), 570
- heart rate and blood pressure (fig.), 574
- 5-HT_{1A} agonist (fig.), 576
- hypertension, hypotension (fig.), 575
- peak elevation of brain temperature (fig.), 572
- physiological responses (fig.), 570
- quiet waking, feeding and active waking (fig.), 576
- respiratory rate, heating trial (fig.), 571
- sleep-wake cycle (fig.), 565
- stress, 568
- suppression, orientation to opening the door (fig.), 576
- waking, sleep (fig.), 577

function, protein phosphorylation, 299

5-HT

- cardiovascular regulation, 573
- mean discharge rates (fig.), 566
- lack of sensitivity, neurotoxic action, capsaicin, 169
- mammalian sensory, acute excitatory effects, capsaicin, 146
- NCS 5-HT, transition from REM sleep to wakefulness (fig.), 566

NRM 5-HT

- alveolar nerve stimulation (fig.), 569
- extracellular action potential (fig.), 564
- mean discharge rate (fig.), 568
- tail-flick trials (fig.), 567

primary afferent

- capsaicin, acute and long-term effects (table), 148
- capsaicin actions, 145

- markers, capsaicin sensitivity (table), 146
 - secondary changes in pathways, 154
- sensory
 - capsaicin, long-term neurotoxic effects, 151
 - consequences of excitation, 149
 - culture, capsaicin, 165
 - intermediate effects, capsaicin, 150
 - in vitro*, effects of capsaicin, 165
 - mechanisms of action, 188
 - mechanisms of selective effects, 174
 - peripheral endings, capsaicin administration, 164
 - peripheral endings, capsaicin action, 184
 - serotonergic, behaving animal, 563
 - thin sensory, capsaicin, 143
- Neuropeptides, therapy of human mental illness, 461
- Neuropeptide Y, corticotropin-releasing factor, actions on HPA axis, 443
- Neuropsychiatric disorders
 - overview, 510
 - serotonin and, 507
 - serotonin receptor subtypes, 579
 - studies of azapirones, 542
 - studies with *m*-chlorophenylpiperazine, 530
- Neurotoxins, synergism, 38, 39
- Neurotransmitter
 - developing systems, interactions, 557
 - excitatory amino acid, 40
 - "false", branched-chain and aromatic amino acids, 37
 - interaction, serotonin, 516
 - liver failure, 39
 - mechanism of action, antipsychotics, 588
 - pathways, regulation of interactions, 325
 - regulation of corticotropin-releasing factor, 437
 - regulation of synthesis, tyrosine hydroxylase, 314
 - release, synapsins, 314
 - synthesis and release, phosphoproteins, presynaptic function, 314
- Neutrophils, nitric oxide, 128
- Nichols, Andrew J. *See* Ruffolo et al., 475
- Nitrate esters
 - coronary vessels, 380
 - in vitro* evaluation of effects, 354
 - in vivo* evaluation of effects, different target organs, 378
 - mode of action, cyclic GMP, 359
 - organic
 - arachidonic acid metabolites, 366
 - chemical structure (fig.), 353
 - clinical use, mechanisms of actions, 351
 - cyclic GMP, cellular calcium homeostasis, 363
 - explanation of tolerance (fig.), 401
 - interaction with endothelium, 370
 - mechanism of, 398
 - other suggested mechanisms, 365
 - pharmacokinetics, 370
 - proposed mechanism of action, cellular level, 357
 - relaxant action, vascular smooth muscle (fig.), 370
 - tissue biotransformation, 367
 - relaxant effect, regional and species differences, 355
 - vasodilatory effects, 356
- Nitrates
 - airway diseases, 391
 - dependency, 404
 - clinical problem, 404
 - mechanism of, 404
 - drug interactions, 406
 - miscellaneous therapeutic uses, 391
 - noncardiovascular uses, 391
 - organic
 - clinical therapeutic use, 382
 - cross-tolerance, 397
 - differences between different target organs, 397
 - tolerance development and dependency, 392
 - peripheral vascular diseases, 391
 - relationship between pharmacokinetics, therapeutic effects, 377
 - side effects, 407
- Nitric oxide
 - Ca²⁺ dependence, citrulline synthesis from L-arginine (fig.), 123
 - effector molecule, immunological reactions, 124
 - endothelium-derived relaxing factor, 111
 - immunologically induced formation *in vivo*, 130
 - inhibition by glucocorticoids, 131
 - inhibition of synthesis, cardiovascular system, 114
 - measured by bioassay and by chemiluminescence, 111
 - novel inhibitors, 116
 - pathological implications, 118
 - pharmacological actions, 120
 - pharmacological and physiological implications, 117
 - physiology, pathophysiology, pharmacology, 109
 - physiology and pathophysiology of synthesis, 126
 - release from porcine aortic endothelial cells, mass spectrometry (fig.), 114
 - synthesis, 114, 120
 - L-arginine, platelet aggregation (fig.), 121
 - macrophages, 124
 - transduction mechanism, soluble guanylate cyclase, 110
- Nitric oxide synthase
 - activity in rat liver, lipopolysaccharide (fig.), 131
 - Ca²⁺-independent (fig.), 129
 - characteristics, 125
 - constitutive and inducible, effect of dexamethasone, rat aorta (fig.), 132
 - induction, effect of cycloheximide, dexamethasone (fig.), 132
 - similarities and differences, constitutive and inducible groups (table), 126
- N^G-Nitro-L-arginine methyl ester, changes in blood pressure (fig.), 117
- Nitroprusside, chemical structure of organic nitrate esters (fig.), 353
- Nociception
 - m*-chlorophenylpiperazine, 538
 - tail-flick test, NRM 5-HT neurons (fig.), 567
- Noradrenaline
 - induced positive inotropic effects, left papillary muscles (fig.), 211
 - induced stimulation of left ventricular adenylate cyclase, antagonism, *beta* adrenoceptors (fig.), 208
- Noradrenergic modulators, cGMP in the cerebellum, 20
- Noradrenergic system, function of, 514
- Norepinephrine, mechanism of action of antipsychotics, 588
- Obsessive-compulsive disorder, studies of *m*-chlorophenylpiperazine, 530
- Olfactory bulb, rat membranes, corticotropin-releasing factor binding, 433
- Ondansetron, antiemesis, 582
- Opiates
 - cerebellar cGMP (table), 8
 - cGMP in the cerebellum, 19
- ORG 5222, cortical 5-HT₂ and striatal pK_i values (table), 593
- Owens, Michael J. and Charles B. Nemeroff. Physiology and pharmacology of corticotropin-releasing factor, 425
- Oxygen consumption, effect of glyceryl trinitrate, ventricular heart muscle (fig.), 366
- Palmer, R. M. J.. *See* Moncada et al., 109
- Panic disorder, studies of *m*-chlorophenylpiperazine, 530
- Pentaerythritol tetranitrate, chemical structure of organic nitrate esters (fig.), 353
- Peptide, release, capsaicin, 177

- Peripheral tissues, localization of corticotropin-releasing factor, 430
- Perlapine, pK_i values (table), 592
- Peroutka, Stephen J. Serotonin receptor subtypes and neuropsychiatric diseases: Focus on 5-HT_{1D} and 5-HT₃ receptor agents, 578
- Pharmacology, developmental, 553, 558
- Phenols, liver enzymes, 39
- Phenylpiperazines
 m-chlorophenylpiperazine, 529
 substituted, studies in humans, 539
- Phosphatidylinositol, turnover, cyclic nature (fig.), 484
- Phosphodiesterase inhibitors, *beta* adrenoceptors, 231
- Phospholipid, metabolism, 484
- Phosphoprotein phosphatases, brain, 312
- Phosphoproteins
 clinical disorders and, 328
 nerve terminal, presynaptic receptors, 319
 postsynaptic function, 319
 presynaptic function, 314
- Phosphorylase kinase, brain, 309
- Pigott, T. A. See Murphy et al., 527
- Pipamperone, pK_i values (table), 592
- Piperazines, *m*-chlorophenylpiperazine, *in vitro* and in animals, 532
- Piribedil, changes in motor activity, cerebellar cGMP (table), 3
- Pitressin, serum sodium level, V₂ antagonists (fig.), 89
- Pituitary
 anterior, corticotropin-releasing factor receptor, feedback- and stress-induced effects, 441
 localization, corticotropin-releasing factor receptors, 433
- Plasma membrane, receptors, regulation, protein phosphorylation (table), 320
- Platelet-activating factor
 binding studies and receptor isolation, 269
 blood platelet receptors, 267
 structure-activity relationships, 268
 uptake and metabolism, 270
- Platelets
 aggregation, L-arginine, nitric oxide synthesis (fig.), 121
 anti-aggregatory activity, effect of L-NIO, L-NMMA (fig.), 126
 cyclic GMP system, organic nitrate esters, 359
 -imipramine binding, 512
 in vivo evaluation of effects, nitrate esters, 381
 pharmacological actions of nitric oxide, 120
 pharmacological receptors, 243
 responses, 245
 serotonin uptake, 512
 stimulus-response coupling, 247
 structure and function, 244
- Polyamines, antagonism, effects of NMDA, quisqualate receptor activation, 14
- Posture, influence on glyceryl trinitrate, 373
- Potassium channel
 activation, 366
 nerve cells, 323
- Practolol, propranolol or, salbutamol-induced tachycardia (fig.), 213
- Prenalterol, *beta* adrenoceptors, 214
- Prolactin, secretion, atypical antipsychotic drugs, 588
- Pro-opiomelanocortin, corticotropin-releasing factor regulation, neuroendocrine function, 435
- Propranolol
 atenolol and, tachycardia (fig.), 212
 practolol or, salbutamol-induced tachycardia (fig.), 213
- Prostaglandins
 Na⁺/H⁺ exchange, *alpha* adrenoceptors, platelets (fig.), 488
 structure-activity relationships, 280
 thromboxane and, 262
- Protein
 phosphorylation
 brain, first messengers (table), 301
 functional importance, 300
 neuronal, multiple sites (table), 302
 neuronal function, 299
 systems, 301
- Protein kinases
 activation by second messengers, 303
 brain, 302
 Ca²⁺/calmodulin-dependent, 306, 308
 Ca²⁺/phospholipid-dependent, 309
 cyclic GMP-dependent, 306
 cyclic nucleotide-dependent, 303
 general mechanisms for activation, 302
 nervous system function (table), 304
 neurofilament, 311
 regulation of ion channels (table), 323
 second messenger-independent, 311
 second messenger-regulated, 303
 tyrosine-specific, 311
- Protein phosphatases
 serine/threonine-specific (table), 312
 tyrosine-specific, 313
- Protein phosphorylation
 Alzheimer's disease, 331
 depolarization-induced Ca²⁺ influx, nerve terminals (table), 316
 regulation of plasma membrane receptors (table), 320
- Protooncogenes, tyrosine-specific protein kinases, 311
- Psychiatric disorders, role of serotonin, 509
- Psychiatric illness, pathophysiology, corticotropin-releasing factor hypersecretion, 457
- Psychiatry, serotonin function, 516
- Purkinje neurons
 differential sensitivity (fig.), 45
 responses, rate meter records, muscimol (fig.), 44
 responses to Ro 14-7437 (fig.), 45
- Pyrogen, activity of DRN-5HT neuron (fig.), 571
- Pyruvate dehydrogenase kinase, activation in brain, 311
- Quipazine, studies in humans, 540
- Quisqualate, low-dose response curves, mouse cerebellar cGMP (fig.), 13
- Raclopride, pED_{50} (table), 594
- Radioligands, *beta*-adrenoceptor antagonist (table), 205
- Rat
 long-term neurotoxic effects, capsaicin, mammalian sensory neurons, 151, 160
 ontogenic shift in neurotoxicity, capsaicin, 186
- Receptors
 adenosine, agonists and antagonists (fig.), 276
 adenosine A₂, characteristics, Nervous and Weaver mice (table), 3
 adenosine 5'-diphosphate
 agonists (fig.), 251
 antagonists (fig.), 252
 affinity profile
 azapirones, 543
 second messenger system effects, 532
 alpha, catecholamines, 255
 benzodiazepine
 antagonists, 57
 GABA, hepatic encephalopathy, 42
 ligands, hepatic encephalopathy, 27, 48
 ligands (fig.), 46
 modulators, 5
 beta, catecholamines, 284
 blood platelets, 243
 cholecystokinin, modulators, 18
 corticotropin-releasing factor, 433
 anterior pituitary, feedback- and stress-induced effects, 441

- biochemical characterization, 433
- CRF-like immunoreactivity (fig.), 460
- distribution, 428
- localization, 433
- localization, pituitary and brain, 433
- signal transduction, second messenger systems, 434
- excitatory amino acid, modulators, 12
- GABA, organization and function, 41
- GABA_A, protein phosphorylation, 320
- GABA_B, agonists, 6
- G-protein coupled, 321
 - schematic model (fig.), 494
- growth factor, 312
- 5-HT₂
 - down-regulation, 594
 - pK_i values, atypical psychotics (table), 592
- 5-HT₃, 582
 - agents (table), 583
 - antagonism, antipsychotic drugs, 598
 - computational model (table), 584
- 5-HT_{1A}, azapirones, 541
- 5-hydroxyindoleacetic acid, subtypes, 515
- influence on development, 555
- intracellular, 322
- ion channel-coupled, 319
- isolation, binding studies, 5-hydroxytryptamine, 259
- muscarinic acetylcholine, 321
- neurotransmitter
 - DHE and sumatriptan interactions (table), 581
 - serotonin, brain development and pharmacology, 553
- nicotinic acetylcholine, 319
- occupancy, positive inotropic effect, isoprenaline (fig.), 226
- plasma membrane, regulation, protein phosphorylation (table), 320
- platelet-activating factor, agonists and antagonists (fig.), 268
- platelet (fig.), 283
- platelet (table), 282
- presynaptic, nerve terminal phosphoproteins, 319
- programmable, 555
- prostaglandin, agonists (fig.), 281
- regulation of function, 319
- serotonin, *see also* 5-HT
 - agonists, neuroendocrine responses, 513
 - antagonism, atypical antipsychotics, 598
 - binding properties of antipsychotics, 592
 - effects, antipsychotic drugs, 587
 - "families", 590
 - physiological effects, 543
 - subtypes, 591
 - subtypes, neuropsychiatric diseases, 579
 - subtypes, physiological effects, 534
- spare, β adrenoceptor agonists, heart, 224
- stimulatory agonists, adenosine 5'-diphosphate, 250
- target tissues, 556
- thromboxane A₂, agonists and antagonists (fig.), 263
- tyrosine kinase-coupled, 322
- vasopressin, subtypes, antagonists, 92
- Renzapride, antiemesis, 582
- Reproductive hormone, function, corticotropin-releasing factor, 442
- Reserpine, corticotropin-releasing factor, actions on HPA axis, 443
- Resiniferatoxin
 - capsaicin and, chemical structure (fig.), 145
 - potent capsaicin agonist, 171
- Respiration
 - activity of DRN 5-HT neurons (fig.), 571
 - depression, cGMP levels, 3
- Rilapine, pK_i values (table), 592
- Risperidone
 - cortical 5-HT₂ and striatal pK_i values (table), 593
 - pED₅₀ (table), 594
- RMI-81582, pK_i values (table), 592
- RNA, messenger
 - corticotropin-releasing factor peptide, 428
 - corticotropin-releasing factor, insulin-induced hypoglycemia (fig.), 441
 - localization of corticotropin-releasing factor, 432
- RO 363, β adrenoceptors, 214
- Ro 14-7437, Purkinje neuron responses (fig.), 45
- Ruffolo, Robert R., Jr., Andrew J. Nichols, Jeffrey M. Stadel, and J. Paul Hieble. Structure and function of α -adrenoceptors, 475
- Ruthenium red, functional antagonist of capsaicin, 182
- SCH 23390, pK_i values (table), 592
- Schizophrenia
 - cerebrospinal fluid CRF-like immunoreactivity (fig.), 459
 - mechanism of action of antipsychotics, 588
 - serotonin, 519
 - studies of *m*-chlorophenylpiperazine, 531
- Serine
 - protein phosphatases, 312
 - protein phosphatases in brain (table), 312
- Serotonin
 - Alzheimer's disease, 519
 - cholinergic interactions, 520
 - dopamine and, 520
 - neuroanatomical relationship, 589
 - false neurotransmitter hypothesis, 39
 - feedback control, 575
 - function
 - affective and personality disorders, 511
 - other psychiatric disorders, 516
 - glucoregulation, 571
 - innervation, nigrostriatal and mesolimbic pathways, 590
 - mechanism of action of antipsychotics, 588
 - mediated behaviors, antipsychotic drugs, 597
 - mesolimbic dopamine pathways, 597
 - neuroleptic-induced catalepsy, 595
 - neuron, extracellular action potential (fig.), 564
 - neuropsychiatric disorders and, 507
 - neurotransmitter interaction, 516
 - other neurotransmitter receptors and, brain development, developmental pharmacology, 553
 - overview of neuropsychiatric disorders, 510
 - pharmacological implications, 521
 - physiological regulation, 569
 - postsynaptic receptor responsiveness, 515
 - precursors, neuroendocrine responses, 512
 - regulation of dopaminergic function, 595
 - role in psychiatric disorders, 509
 - schizophrenia, 519
 - selective arylpiperazines, effects in humans, 527
 - uptake in platelets, 512
- Serotonin receptor agonists, neuroendocrine responses, 513
- Sertindole, cortical 5-HT₂ and striatal pK_i values (table), 593
- Setoperone, pK_i values (table), 592
- Sexual function, *m*-chlorophenylpiperazine, 538
- Shunt, portal-systemic, reduction, hepatic encephalopathy, 54
- Siever, Larry J., René S. Kahn, Brian A. Lawlor, Robert L. Trestman, Timothy L. Lawrence, and Emil F. Coccaro. Critical issues in defining the role of serotonin in psychiatric disorders, 509
- Skolnick, P. *See* Basile et al., 27
- Sleep
 - m*-chlorophenylpiperazine, 538
 - REM, wakefulness transition, NCS 5-HT neuron (fig.), 566
 - wake-arousal continuum, 5-HT neurons (fig.), 566
 - wake-arousal cycle, 564

- wake cycle, DRN 5-HT neuron (fig.), 565
- SM-9018, cortical 5-HT₂ and striatal pK_i values (table), 593
- Sodium, -hydrogen exchange, 487
 - transduction, α_2 -adrenoceptors and platelets (fig.), 488
- Sodium channels, voltage-sensitive, 323
- Sodium chloride, calcium and, intracellular accumulation, neurotoxicity, 181
- Stadel, Jeffrey M. *See* Ruffolo et al., 475
- Stress
 - alprazolam and, corticotropin-releasing factor concentrations (fig.), 455
 - brain 5-HT, 568
 - corticotropin-releasing factor neurons, 453
 - drug and behavioral effects, cerebellar cGMP, 3
 - secondary effects, 453
- Suicide, controls and, composite Scatchard analysis, frontal cortical sample (fig.), 460
- Sulphydryl, replenishment, tolerance, organic nitrates, 402
- Sumatriptan
 - biochemical and neurochemical effects, 581
 - clinical efficacy (table), 580
 - clinical studies, 579
 - DHE and, neurotransmitter receptor (table), 581
 - history of (table), 579
 - pharmacology of, 580
 - side effect profile (table), 580
- Synapsins
 - regulation of neurotransmitter release, 314
 - variants and alcoholism, 329
- Tachycardia
 - atenolol and propranolol (fig.), 212
 - salbutamol-induced, practolol or propranolol (fig.), 213
- Tau factor
 - microtubule function, 332
 - phosphorylation, neurofibrillary tangles, 332
- Temperature
 - brain, DRN 5-HT neuron (fig.), 572
 - m*-chlorophenylpiperazine, 534
 - physiological effects, serotonin receptors, 543
 - serotonin-selective arylpiperazines, 527
- Tenilapine, pK_i values (table), 592
- 1,2,3,4-Tetranitratobutan, concentration-effect curve (fig.), 355
- Thermoregulation, brain 5-HT, 570
- Thioridazine, pED₅₀ (table), 594
- Threitol tetranitrate, concentration-effect curve (fig.), 355
- Threonine, -specific protein phosphatases, 312
 - brain (table), 312
- Thrombin, blood platelet receptors, 271
- Thromboxane, prostaglandins and, 262
- Thromboxane A₂, Na⁺/H⁺ exchange, α adrenoceptors, platelets (fig.), 488
- Thyrotropin-releasing hormone, analogues, 18
- Tiospirone
 - pED₅₀ (table), 594
 - pK_i values (table), 592
- Torfgård, Kristina. *See* Ahlner et al., 351
- Trestman, Robert L. *See* Siever et al., 509
- TRH peptides, cerebellar cGMP (table), 9
- Trinitro toluene, chemical structure of organic nitrate esters (fig.), 353
- Tryptophan, plasma, 511
- Tubulin, phosphorylation by cAMP-dependent protein kinase, 332
- Tyrosine, -specific protein phosphatases, 313
- Tyrosine hydroxylase, regulation of neurotransmitter synthesis, 314
- Urine
 - excretion
 - osmolality, pitressin (fig.), 89
 - V₂ antagonist (fig.), 88
 - vasopressin antagonists (fig.), 87
- Vasculature, nitric oxide, 110, 129
- Vasodilation
 - induced by nitrate esters, 354
 - nitrate esters, 356
- Vasodilators, other antianginal drugs and, drug interactions, nitrates, 407
- Vasopressin
 - antagonists
 - antidiuretic responses (table), 77
 - antidiuretic responses, 76
 - bioassay, definition of antagonist potency, 75
 - central and peripheral circulation, 78
 - change in urine excretion (fig.), 87
 - chemical structure and biological activity, 75
 - chemical structure of d(CH₂)₅Tyr(Me)AVP (fig.), 77
 - chemical structure of V₂ antagonists (fig.), 77
 - elevated plasma arginine-vasopressin levels, 96
 - pharmacology and clinical perspectives, 73
 - physiological and pathophysiological roles, 78
 - potency, 76
 - pressor responses, 76
 - release, adrenocorticotrophic hormone, 90
 - serum osmolality, water content of brain (table), 90
 - serum sodium level, pitressin (fig.), 89
 - sodium excretion (fig.), 89
 - synthesis, 75
 - therapeutic effects, 97
 - treatment, clinical significance, 95
 - urine excretion and osmolality, pitressin (fig.), 89
 - urine excretion (fig.), 88
 - V₂ and V₁ antagonists with opening rings (fig.), 79
 - vasopressor responses (table), 77
 - water metabolism, 86
 - binding studies and receptor isolation, 261
 - structure-activity relationships, 261
- Visual-evoked response
 - abnormalities (fig.), 43
 - GABA/benzodiazepine receptor complex, 42
- Walaas, Sven Ivar and Paul Greengard. Protein phosphorylation and neuronal function, 299
- Water
 - content of brain, serum osmolality, vasopressin antagonist (table), 90
 - metabolism, role, V₂ antagonists, 86
- Whitaker-Azmitia, Patricia M. Role of serotonin and other neurotransmitter receptors in brain development: Basis for developmental pharmacology, 553
- Wilker, Jeffrey C. and Wilmot, Carole A. Serotonin and neuropsychiatric disorders, 507
- Wilmot, Carole A. *See* Wilker et al., 507
- Wood, Paul L. Pharmacology of the second messenger, cyclic guanosine 3',5'-monophosphate, in the cerebellum, 1
- Xamoterol, β adrenoceptors, 214
- Yohimbine, binding, competition by agonists and antagonists (table), 498
- Zacopride, clinical status (table), 583
- Zotepine, pK_i values (table), 592